Organogenesis Holdings Inc. Class A Common Stock (ORGO)

FairStock Score: 76/100 — HIGH CONVICTION

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for durable earning power bought at a sensible price, and Organogenesis fails the first test right now. In fiscal Q2 2026, the quarter ended 2026-06-30, the company filed revenue of $43.8 million, net income of -$96.3 million, and diluted EPS of -$0.77. In fiscal Q1 2026, ended 2026-03-31, it filed revenue of $37.2 million, net income of -$53.2 million, and EPS of -$0.44. Compare fiscal Q2 2025, ended 2025-06-30: revenue was $101.0 million, net income was -$9.4 million, and EPS was -$0.10. That is a severe deterioration. The annual record had been better: FY2025 revenue $564.2 million, net income $37.0 million, EPS $0.15; FY2024 revenue $482.0 million, net income $861,000, EPS -$0.01; FY2023 revenue $433.1 million, net income $4.9 million, EPS $0.04. FairStock's Lynch rule calls it a STALWART based on 16.5% five-year profit growth and 10.8% revenue growth, but the current numbers argue otherwise. The wound-care products may have some regulatory and clinical barriers, but the figures show no moat strong enough to prevent a revenue collapse. At the 2026-10-13 close of $1.21, market cap is $155.7 million. FairStock ratios show P/B 1.05, negative P/E -1.53, ROE -25.92%, ROCE -4.11%, D/E 0.23, Piotroski 4/9, and Altman Z 0.37. TTM free cash flow is $20.8 million, a 13.4% FCF yield, which could be attractive if sustainable. But a 0.37 Z-score signals distress, and without stable profits there is no margin of safety in Graham's terms. This is a speculative turnaround, not a steady compounder.

In plain English: Organogenesis makes regenerative medicine products for wound care and surgical/sports medicine. The business looked profitable in fiscal 2025, but in the first half of fiscal 2026 it lost large amounts and the latest quarter's revenue was much lower than a year earlier. At $1.21, the shares are near their 52-week low and around the value of what the company owns minus what it owes, which may look cheap, but the losses make the price risky rather than clearly cheap.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer